Skip to main content
NATR
NASDAQ Life Sciences

Nature's Sunshine Cuts FY26 Guidance After Q3 Sales Fall 9% and EPS Halves to $0.11

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Food & Beverage Stocks · Consumer
Sentiment info
Negative
Importance info
8
Price
$10.8
Mkt Cap
$225.926M
52W Low
$11.92
52W High
$28.14
52W Position info
9.4% below low
Off High info
62% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

NATR is trading near its 52-week low of $11.92 (9.4% below the low).

Summary

Q3 sales fell 9% to $116.6 million and EPS came in at $0.11 versus $0.30 a year ago, prompting a cut to full-year sales and Adjusted EBITDA guidance. Cash of $89.4 million and no debt limit near-term risk, but China weakness and a 64.8% tax rate drove the miss.


Key Events · Earnings and Guidance · NATR

  • Q3 Sales Fall 9% to $116.6M

    Net sales came in at $116.6 million versus $128.3 million a year earlier, a 9.1% decline (7.2% in constant currency).

  • EPS Halves to $0.11

    GAAP net income attributable to common shareholders fell to $1.9 million, or $0.11 per diluted share, from $5.3 million ($0.30). Adjusted EBITDA dropped to $11.1 million from $15.2 million.

  • Full-Year Guidance Cut

    FY26 net sales are now guided to $460-$470 million (from $490-$500 million) and Adjusted EBITDA to $44-$48 million (from $48-$52 million).

  • China and Asia Weakness

    Asia net sales fell 14.9% to $55.1 million, while China dropped 48.8% after operational disruptions to the consultant leadership base. The effective tax rate rose to 64.8% from 42.8%.


Analysis · NATR · Life Sciences

The full-year outlook is now lower: sales are guided to $460-$470 million from $490-$500 million, and Adjusted EBITDA to $44-$48 million from $48-$52 million. Q3 itself was weak, with net income down to $1.9 million ($0.11 per diluted share) from $5.3 million ($0.30), China sales off 48.8%, and the tax rate jumping to 64.8%. The balance sheet offers some cushion — $89.4 million of cash and zero debt — but the earnings trajectory is deteriorating and the stock is already near its 52-week low.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 41.6% of the 1192 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NATR was trading at $10.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $225.9M. The 52-week trading range was $11.92 to $28.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NATR - Latest Insights

NATR
Nov 04, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.55
Real-time Price: $10.80 info
Change: -$0.750 (-6%) info
Market Cap: $225.926M info
NATR
Aug 10, 2026, 7:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $15.77
Real-time Price: $10.80 info
Change: -$4.97 (-32%) info
Market Cap: $225.926M info
NATR
Aug 06, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $17.95
Real-time Price: $10.80 info
Change: -$7.15 (-40%) info
Market Cap: $225.926M info
NATR
Aug 06, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.40
Real-time Price: $10.80 info
Change: -$5.60 (-34%) info
Market Cap: $225.926M info
NATR
May 11, 2026, 8:53 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $24.23
Real-time Price: $10.80 info
Change: -$13.43 (-55%) info
Market Cap: $225.926M info